35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, announced the closing of an oversubscribed $53 million Series C financing. The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.

The Series C financing was led by Frazier Life Sciences with participation from additional new investors that included Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, Columbia Threadneedle, as well as from existing investors VenBio, Surveyor Capital, Logos Capital and Marshall Wace.